Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002823 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer
A Phase 3 study, sponsored by Gustave Roussy, Cancer Campus, Grand Paris.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,300
- Enrollment target
NCT00002823 is a Phase 3 study that has completed, run by Gustave Roussy, Cancer Campus, Grand Paris. The registered enrollment target is 3,300 participants.
The verdict
NCT00002823, a Phase 3 study, has completed, sponsored by Gustave Roussy, Cancer Campus, Grand Paris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,300 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy given after surgery is more effective than surgery alone for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy following surgery with that of surgery alone in treating patients who have stage I, stage II, or stage IIIA non-small cell lung cancer.
Interventions
- DRUG cisplatin
- DRUG etoposide
- DRUG vinorelbine tartrate
- DRUG vinblastine sulfate
- DRUG vindesine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,300 participants |
| Start Date | 1995-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002823
The ClinicalTrials.gov registry entry for NCT00002823 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gustave Roussy, Cancer Campus, Grand Paris, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00002823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002823 about?
NCT00002823 is a clinical study titled "Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy given after surgery is more effective than surgery alone for non-small cell lung cancer. PURPOSE: Randomized phase III trial to com...
What is the current status of trial NCT00002823?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,300 participants. The study started on 1995-02.
What interventions are being tested in trial NCT00002823?
The interventions under investigation include: cisplatin (DRUG), etoposide (DRUG), vinorelbine tartrate (DRUG), vinblastine sulfate (DRUG), vindesine (DRUG).
Who is sponsoring clinical trial NCT00002823?
This trial is sponsored by Gustave Roussy, Cancer Campus, Grand Paris, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.